References
- Ezzati M, Lopez AD. Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob. Control13, 288–295 (2004).
- World Bank. Curbing the epidemic: governments and the economics of tobacco Control [report], World Bank, WA, USA (1999).
- Lightwood JM, Glantz SA. Short-term economic and health benefits of smokingcessation: myocardial infarction and stroke. Circulation96, 1089–1096 (1997).
- Carrozzi L, Pistelli F, Viegi G. Pharmacotherapy for smoking cessation. Ther. Adv. Respir. Dis.2(5), 301–317 (2008).
- Coe JW, Brooks PR, Vetelino MG et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem.48, 3474–3477 (1005).
- Jorenby DE, Hays JT, Rigotti NA et al. Efficacy of varenicline, and α4β2 nicotinic receptor partial agonist, vs placebo or sustained-release bupropion for smoking-cessation: a randomized controlled trial. JAMA296, 56–63 [Erratum, JAMA296, 1355 (2006)].
- Gonzales D, Rennard SI, Nides M et al. Varenicline, an α4β2 nicotinic receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA296, 47–55 (2006).
- Nides M, Oncken C. Gonzales D et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist,; results from a 7-week, randomized, placebo and bupropion-controlled trial with 1-year follow up. Arch. Intern. Med.166, 1561–1568 (2006).
- Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. (3), CD006103 (2006).
- Tønnesen P, Carrozzi L, Fagerstrøm KO et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur. Respir. J.29, 390–417 (2007).
- Cornuz J, Gilbert A, Pinget C et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparion. Tob. Control15, 152–159 (2006).
- Barendregt J, Bonneux L, van der Maas PJ. The health care cost of smoking. N. Engl. J. Med.337(15), 1052–1057 (1997).
- Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics26(6), 497–511 (2008).
- Orme ME, Hogue SL, Kennedy LM et al. Development of the health and economic consequences of smoking interactive model. Tob. Control10, 55–61 (2001).
- Hays JT, Ebbert JO. Varenicline for tobacco dependence, N. Engl. J. Med.359, 2018–2024 (2008).
- Bolin K, Mörk AC, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking-cessation therapy – cost-utility results for Sweden 2003. Resp. Med.102, 699–710 (2008).
- Igarashi A, Takuma H, Fukuda T, Tsutani K. Cost–utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics27(3), 247–261 (2009).
- Jackson KC, Nahoopii R, Said Q, Dirani R, Brixner D. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J. Occup. Environ. Med.49(4), 453–460 (2007).
- Weis WL. Can you afford to hire smokers? Pers. Adm.26, 71–73, 75–78 (1981).
- Bertram MY, Lim SS, Wallace AL, Vos T. Costs and benefits of smoking cessation aids, making a case for public reimbursement of nicotine replacement therapy in Australia. Tob. Control16, 255–260 (2007).
- Hering T. Modern medical support for smoking cessation. Internist50(1), 95–100 (2009).
- Mas-Colell A, Whinston RD, Green JA, Microeconomic Theory. Oxford University Press, Oxford, UK (1995).
- Halpern MT, Dirani R, Schmier JK. The cost effectiveness of varenicline for smoking cessation. Manag. Care Interface20(10), 18–25 (2007).
- Heitjan DF, Asch DA, Ray R et al. Cost–effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J.8(6), 391–399 (2008).
- Hoogendorn M, Welsing P, Rutten-van Mölken M. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in The Netherlands. Curr. Med. Res. Op.24, 51–61 (2008).
- Poulsen PB, Dollerup J, Keiding H. The cost–effectiveness of varenicline in smoking cessation in Denmark. Poster. Presented at: ISPOR 11th Annual European Congress. Athens, Greece, 8–11 November 2008.
- Fernández de Bobadilla Osorio J, Sánchez-Maestre C, Brosa Riestra M, Arroyo O, Sanz de Burgoa V, Wilson K. Cost effectiveness analysis of varenicline (Champix®) for the treatment of smoking in Spain. An. Med. Interna25(7), 342–348 (2008).
Websites
- Stapleton J. Is varenicline cost effective enough to be funded by the NHS now? (2006). www.scsrn.org/policy_guidance/Varenicline_NHS_CE.pdf
- NHS guidance: varenicline (2007). www.nice.org.uk:80/guidance/index.jsp?action=byID&r=true&o=11718